Virtual Poster Session in CML From Stockholm
Virtual Poster
Virtual Poster

Virtual Poster Session in CML From Stockholm

Practical Application of Key Data Presented During the 2018 European Hematology Annual Meeting

View Activities

Not a member of My prIME? Join now for instant access.

The information in this activity is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before participating in the activity. This activity may contain information on products outside the approved indications where you practice.

Stay current on the latest updates in chronic myeloid leukemia (CML). View abstract presentations and downloadable slides from the 2018 Annual European Hematology Meeting.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

IME

IME

Release Date

Release Date

Jun 22, 2018

Expiration Date

Jun 22, 2019

Timothy Hughes, MD, FRACP, FRCPA, FAAHMS

Abstract #PF377: Long-term treatment-free remission (TFR) following second-line (2L) NIL in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTop 144-wk results

Featured Expert: Timothy Hughes, MD, FRACP, FRCPA, FAAHMS

Giuseppe Saglio, MD

Abstract #PF368: Long-term treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) following frontline (1L) NIL: Results from ENESTfreedom

Featured Expert: Giuseppe Saglio, MD

Richard Clark, MA, MD, MRCP, FRCPath

Abstract #S809:  Final results of the DESTINY study of de-escalation and stopping treatment in chronic myeloid leukemia

Featured Expert: Richard Clark, MA, MD, MRCP, FRCPath

Dennis Kim, MD, PhD

Abstract #PF379: The value of BCR-ABL qPCR level and doubling time (DT) to predict successful treatment-free remission after IMAT discontinuation: Treatment-free remission accomplished by DAS (TRAD) trial

Featured Expert: Dennis Kim, MD, PhD

  • Richard Clark, MA, MD, MRCP, FRCPathUniversity of Liverpool
    Liverpool, United Kingdom
  • Timothy Hughes, MD, FRACP, FRCPA, FAAHMSUniversity of Adelaide
    Adelaide, South Australia, Australia
  • Dennis Kim, MD, PhDPrincess Margaret Cancer Centre
    University of Toronto
    Toronto, Canada
  • Giuseppe Saglio, MDUniversity of Turin
    Turin, Italy

This educational activity is designed to meet the needs of practicing hematologists, oncologists, oncology nurses, researchers, and other health care professionals involved and/or interested in the management of patients with hematologic malignancies and their complications.

After successful completion of this educational activity, participants should be able to:

  • Evaluate clinical evidence supporting novel therapeutic strategies in CML and compare with established treatment options
  • Select appropriate biomarkers for predicting therapeutic response in CML
  • Identify appropriate clinical trials in which to enroll patients with CML

ALL

Abstract #S1565: Outcomes of young adult patients (≥18-25 years) with relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL) following treatment with chimeric antigen receptor (CAR) T-cell therapy
Featured Expert: Jae Park, MD

Abstract #S1569: Outcomes of patients with relapsed/refractory acute lymphoblastic leukemia treated with prior blinatumomab in ZUMA-3, a study of KTE-CD19, and Anti-CD19 chimeric antigen receptor (CAR) T cell therapy
Featured Expert: Jae Park, MD

Abstract #PF177: Inotuzumab ozogamicin treatment in patients with relapsed/refractory acute lymphoblastic leukemia: Analysis from INO-VATE by bone marrow blast percentage
Featured Expert: David I. Marks, MBBS, PhD, FRACP, FRCPath

CML

Abstract #PF377: Long-term treatment-free remission (TFR) following second-line (2L) nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTop 144-wk results
Featured Expert: Timothy Hughes, MD, FRACP, FRCPA, FAAHMS

Abstract #PF368: Long-term treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) following frontline (1L) nilotinib (NIL): Results from ENESTfreedom
Featured Expert: Giuseppe Saglio, MD

Abstract #S809: Final results of the DESTINY study of de-escalation and stopping treatment in chronic myeloid leukemia
Featured Expert: Richard Clark, MA, MD, MRCP, FRCPath

Abstract #PF379: The value of BCR-ABL qPCR level and doubling time (DT) to predict successful treatment-free remission after imatinib discontinuation: Treatment-free remission accomplished by dasatinib (TRAD) trial
Featured Expert: Dennis Kim, MD, PhD

DLBCL

Abstract #PF628: An updated analysis of JULIET, a global pivotal phase 2 trial of tisagenlecleucel in adult patients with relapsed or refractory (R/R) diffuse large B-Cell lymphoma
Featured Expert: Gilles Salles, MD, PhD

Abstract #S800: Updated safety and long term clinical outcomes in transcend NHL 0001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL
Featured Expert: Jeremy Abramson, MD

Abstract #S802: Adding polatuzumab vedotin (POLA) to bendamustine and rituximab (BR) Treatment improves survival in patients with relapsed/refractory DLBCL: Results of a phase 2 clinical trial    Featured Expert: Laurie Sehn, MD

Abstract #PF259: Axicabtagene ciloleucel (Axi-cel) in patients with refractory large B cell lymphoms: Durability of response in ZUMA-1
Featured Expert: Christian Gisselbrecht, MD, PhD

MPN

Abstract #PF628: Comparison of ruxolitinib and real-world best available therapy in terms of overall survival and thrombosis in patients with polycythemia vera who are resistant or intolerant to hydroxyurea
Featured Expert: Alberto Alvarez-Larran, MD

Abstract #PF623: Safety and efficacy of ruxolitinib (RUX) in patients (Pts) with DIPSS low-risk myelofibrosis (MF) in the phase 3B expanded-access JUMP study
Featured Expert: Haifa Kathrin Al-Ali, MD

Abstract #PF616: Predictors of response to ruxolitinib (RUX) in patients (pts) with myelofibrosis (MF) in the phase 3B expanded-access JUMP study
Featured Expert: Haifa Kathrin Al-Ali, MD

Abstract #S132: Comparison of long-term efficacy and safety of ropeginterferon alfa-2B vs HU in polycythemia vera patients aged below or above 60 years: Two-year analysis from the PROUD/CONTIUATION phase III trials
Featured Expert: Jean-Jacques Kiladjian, MD, PhD

Abstract #S130: Frequent immunoglobulin rearrangement, jak1/2 inhibition and aggressive B-cell lymphoma development in patients with myelofibrosis
Featured Expert: Jean-Jacques Kiladjian, MD, PhD

This educational activity is supported by a grant from Novartis Oncology.

Independent Medical Education

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of IME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality IME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Clark has disclosed that he has received consulting fees from Novartis and Pfizer. Furthermore, he served as an independent contractor for Bristol-Myers Squibb, Novartis, and Pfizer. He has also been speaking and teaching for Novartis and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Hughes has disclosed that he has received consulting fees from Bristol-Myers Squibb, Novartis, and Takeda. Furthermore, he is a member of the advisory committee or review panel for Novartis, Bristol-Myers Squibb, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Kim has disclosed that he has received a research grant from Bristol-Myers Squibb Canada. Furthermore, he has been a member of a national advisory board for Bristol-Myers Squibb Canada and Novartis Canada. He also disclosed receipt of fees for educational speaking from Bristol-Myers Squibb and Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Saglio has nothing to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Janice Galleshaw, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Briana Betz, PhD (scientific content reviewer/planner) – no relevant financial relationships
  • Jessica Mastrodomenico, MPH (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.